Single-Cell Multiomics Reveals TCR Clonotype-Specific Phenotype and Stemness Heterogeneity of T-ALL Cells

Abstract

T-cell acute lymphoblastic leukaemia (T-ALL) is a heterogeneous malignant disease with high relapse and mortality rates. To characterise the multiomics features of T-ALL, we conducted integrative analyses using single-cell RNA, TCR and chromatin accessibility sequencing on pre- and post-treatment peripheral blood and bone marrow samples of the same patients. We found that there is transcriptional rewiring of gene regulatory networks in T-ALL cells. Some transcription factors, such as TCF3 and KLF3, showed differences in activity and expression levels between T-ALL and normal T cells and were associated with the prognosis of T-ALL patients. Furthermore, we identified multiple malignant TCR clonotypes among the T-ALL cells, where the clonotypes consisted of distinct combinations of the same TCR α and β chain per patient. The T-ALL cells displayed clonotype-specific immature thymocyte cellular characteristics and response to chemotherapy. Remarkably, T-ALL cells with an orphan TCRβ chain displayed the strongest stemness and resistance to chemotherapy. Our study provided transcriptome and epigenome characterisation of T-ALL cells categorised by TCR clonotypes, which may be helpful for the development of novel predictive markers to evaluate treatment effectiveness for T-ALL.

Keywords

clonotype-specific T-ALL characteristics / immature thymocyte / single-cell multiomics / T-cell acute lymphoblastic leukemia (T-ALL) / T-cell receptor (TCR) clonotype

References

[1] M. Sanchez-Martin and A. Ferrando, “The NOTCH1-MYC Highway Toward T-Cell Acute Lymphoblastic Leukemia,” Blood 129, no. 9 (2017): 1124-1133.

[2] M. Simonin, G. P. Andrieu, R. Birsen, et al., “Prognostic Value and Oncogenic Landscape of TP53 Alterations in Adult and Pediatric T-ALL,” Blood 141, no. 11 (2023): 1353-1358.

[3] M. Simonin, L. Lhermitte, M. E. Dourthe, et al., “IKZF1 Alterations Predict Poor Prognosis in Adult and Pediatric T-ALL,” Blood 137, no. 12 (2021): 1690-1694.

[4] M. Simonin, A. Schmidt, C. Bontoux, et al., “Oncogenetic Landscape and Clinical Impact of IDH1 and IDH2 Mutations in T-ALL,” Journal of Hematology & Oncology 14, no. 1 (2021): 74.

[5] D. I. Marks and C. Rowntree, “Management of Adults With T-Cell Lymphoblastic Leukemia,” Blood 129, no. 9 (2017): 1134-1142.

[6] L. C. Fleischer, H. T. Spencer, and S. S. Raikar, “Targeting T Cell Malignancies Using CAR-Based Immunotherapy: Challenges and Potential Solutions,” Journal of Hematology & Oncology 12, no. 1 (2019): 141.

[7] Y. Kogure, T. Kameda, J. Koya, et al., “Whole-Genome Landscape of Adult T-Cell Leukemia/Lymphoma,” Blood 139, no. 7 (2022): 967-982.

[8] L. Alberti-Servera, S. Demeyer, I. Govaerts, et al., “Single-Cell DNA Amplicon Sequencing Reveals Clonal Heterogeneity and Evolution in T-Cell Acute Lymphoblastic Leukemia,” Blood 137, no. 6 (2021): 801-811.

[9] A. C. Carpenter and R. Bosselut, “Decision Checkpoints in the Thymus,” Nature Immunology 11, no. 8 (2010): 666-673.

[10] F. Famili, A. S. Wiekmeijer, and F. J. Staal, “The Development of T Cells From Stem Cells in Mice and Humans,” Future Science OA 3, no. 3 (2017): FSO186.

[11] D. K. Shah and J. C. Zuniga-Pflucker, “An Overview of the Intrathymic Intricacies of T Cell Development,” Journal of Immunology 192, no. 9 (2014): 4017-4023.

[12] A. Krueger, N. Zietara, and M. Lyszkiewicz, “T Cell Development by the Numbers,” Trends in Immunology 38, no. 2 (2017): 128-139.

[13] N. Tamehiro, H. Oda, M. Shirai, and H. Suzuki, “Overexpression of RhoH Permits to Bypass the Pre-TCR Checkpoint,” PLoS One 10, no. 6 (2015): e0131047.

[14] A. Dutta, B. Zhao, and P. E. Love, “New Insights Into TCR Beta-Selection,” Trends in Immunology 42, no. 8 (2021): 735-750.

[15] T. Kreslavsky, M. Gleimer, M. Miyazaki, et al., “Beta-Selection-Induced Proliferation Is Required for Alphabeta T Cell Differentiation,” Immunity 37, no. 5 (2012): 840-853.

[16] T. K. Teague, C. Tan, J. H. Marino, et al., “CD28 Expression Redefines Thymocyte Development During the Pre-T to DP Transition,” International Immunology 22, no. 5 (2010): 387-397.

[17] I. Aifantis, M. Mandal, K. Sawai, A. Ferrando, and T. Vilimas, “Regulation of T-Cell Progenitor Survival and Cell-Cycle Entry by the Pre-T-Cell Receptor,” Immunological Reviews 209 (2006): 159-169.

[18] C. S. Tremblay, T. Hoang, and T. Hoang, “Early T Cell Differentiation Lessons From T-Cell Acute Lymphoblastic Leukemia,” Progress in Molecular Biology and Translational Science 92 (2010): 121-156.

[19] Y. Onishi, E. Furukawa, M. Kamata, et al., “Outcomes of Adult Patients With Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia/Lymphoma (ALL) and Non-ETP T-ALL,” International Journal of Hematology 117, no. 5 (2023): 738-747.

[20] P. Borgulya, H. Kishi, Y. Uematsu, and H. von Boehmer, “Exclusion and Inclusion of Alpha and Beta T Cell Receptor Alleles,” Cell 69, no. 3 (1992): 529-537.

[21] A. M. Jackson and M. S. Krangel, “Turning T-Cell Receptor Beta Recombination on and Off: More Questions Than Answers,” Immunological Reviews 209 (2006): 129-141.

[22] E. Padovan, G. Casorati, P. Dellabona, S. Meyer, M. Brockhaus, and A. Lanzavecchia, “Expression of Two T Cell Receptor Alpha Chains: Dual Receptor T Cells,” Science 262, no. 5132 (1993): 422-424.

[23] H. T. Petrie, F. Livak, D. G. Schatz, A. Strasser, I. N. Crispe, and K. Shortman, “Multiple Rearrangements in T Cell Receptor Alpha Chain Genes Maximize the Production of Useful Thymocytes,” Journal of Experimental Medicine 178, no. 2 (1993): 615-622.

[24] A. Warmflash and A. R. Dinner, “A Model for TCR Gene Segment Use,” Journal of Immunology 177, no. 6 (2006): 3857-3864.

[25] M. J. T. Stubbington, T. Lonnberg, V. Proserpio, et al., “T Cell Fate and Clonality Inference From Single-Cell Transcriptomes,” Nature Methods 13, no. 4 (2016): 329-332.

[26] A. A. Eltahla, S. Rizzetto, M. R. Pirozyan, et al., “Linking the T Cell Receptor to the Single Cell Transcriptome in Antigen-Specific Human T Cells,” Immunology and Cell Biology 94, no. 6 (2016): 604-611.

[27] B. L. Brady, N. C. Steinel, and C. H. Bassing, “Antigen Receptor Allelic Exclusion: An Update and Reappraisal,” Journal of Immunology 185, no. 7 (2010): 3801-3808.

[28] C. Y. Huang, B. P. Sleckman, and O. Kanagawa, “Revision of T Cell Receptor Alpha Chain Genes Is Required for Normal T Lymphocyte Development,” Proceedings of the National Academy of Sciences of the United States of America 102, no. 40 (2005): 14356-14361.

[29] S. Chen, X. Huang, H. Zheng, et al., “The Evolution of Malignant and Reactive Gammadelta + T Cell Clones in a Relapse T-ALL Case After Allogeneic Stem Cell Transplantation,” Molecular Cancer 12 (2013): 73.

[30] E. H. Joo, J. H. Bae, J. Park, et al., “Deconvolution of Adult T-Cell Leukemia/Lymphoma With Single-Cell RNA-Seq Using Frozen Archived Skin Tissue Reveals New Subset of Cancer-Associated Fibroblast,” Frontiers in Immunology 13 (2022): 856363.

[31] J. Zhang, Y. Duan, P. Wu, et al., “Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-Resistance in T-Cell Acute Lymphoblastic Leukemia,” Blood 142 (2023): 846.

[32] M. Cordes, K. Cante-Barrett, E. B. van den Akker, et al., “Single-Cell Immune Profiling Reveals Thymus-Seeding Populations, T Cell Commitment, and Multilineage Development in the Human Thymus,” Science Immunology 7, no. 77 (2022): eade0182.

[33] J. E. Park, R. A. Botting, C. Dominguez Conde, et al., “A Cell Atlas of Human Thymic Development Defines T Cell Repertoire Formation,” Science 367, no. 6480 (2020): eaay3224.

[34] F. Wang, Z. Qi, Y. Yao, et al., “Exploring the Stage-Specific Roles of Tcf-1 in T Cell Development and Malignancy at Single-Cell Resolution,” Cellular & Molecular Immunology 18, no. 3 (2020): 644-659.

[35] C.-S. Li, F. Tang, P. Zhang, et al., “Trap1a Is an X-Linked and Cell-Intrinsic Regulator of Thymocyte Development,” Cellular & Molecular Immunology 14, no. 8 (2016): 685-692.

[36] Y. Zhao, J. Cao, H. Xu, et al., “Optimizing In Vitro T Cell Differentiation by Using Induced Pluripotent Stem Cells With GFP-RUNX1 and mCherry-TCF7 Labelling,” Cell Proliferation 57 (2024): e13661.

[37] I. H. Goenawan, K. Bryan, and D. J. Lynn, “DyNet: Visualization and Analysis of Dynamic Molecular Interaction Networks,” Bioinformatics 32, no. 17 (2016): 2713-2715.

[38] L. Su, Z. Hu, and Y. G. Yang, “Role of CXCR4 in the Progression and Therapy of Acute Leukaemia,” Cell Proliferation 54, no. 7 (2021): e13076.

[39] D. Caracciolo, A. Mancuso, N. Polera, et al., “The Emerging Scenario of Immunotherapy for T-Cell Acute Lymphoblastic Leukemia: Advances, Challenges and Future Perspectives,” Experimental Hematology & Oncology 12, no. 1 (2023): 5.

[40] Y. Tan, L. Shan, L. Zhao, et al., “Long-Term Follow-Up of Donor-Derived CD7 CAR T-Cell Therapy in Patients With T-Cell Acute Lymphoblastic Leukemia,” Journal of Hematology & Oncology 16, no. 1 (2023): 34.

[41] G. S. Gulati, S. S. Sikandar, D. J. Wesche, et al., “Single-Cell Transcriptional Diversity Is a Hallmark of Developmental Potential,” Science 367, no. 6476 (2020): 405-411.

[42] H. Zheng, X. Wang, Y. Ma, et al., “The TCR Gammadelta Repertoire and Relative Gene Expression Characteristics of T-ALL Cases With Biclonal Malignant Vdelta1 and Vdelta2 T Cells,” DNA and Cell Biology 33, no. 1 (2014): 49-56.

[43] C. Huang and O. Kanagawa, “Ordered and Coordinated Rearrangement of the TCR Alpha Locus: Role of Secondary Rearrangement in Thymic Selection,” Journal of Immunology 166, no. 4 (2001): 2597-2601.

[44] H. P. Dai, W. Cui, Q. Y. Cui, et al., “Haploidentical CD7 CAR T-Cells Induced Remission in a Patient With TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma,” Biomarker Research 10, no. 1 (2022): 6.

[45] P. Anand, A. Guillaumet-Adkins, V. Dimitrova, et al., “Single-Cell RNA-Seq Reveals Developmental Plasticity With Coexisting Oncogenic States and Immune Evasion Programs in ETP-ALL,” Blood 137, no. 18 (2021): 2463-2480.

[46] F. Tarantini, C. Cumbo, L. Anelli, et al., “Inside the Biology of Early T-Cell Precursor Acute Lymphoblastic Leukemia: The Perfect Trick,” Biomarker Research 9, no. 1 (2021): 89.

[47] J. Frede, P. Anand, N. Sotudeh, et al., “Dynamic Transcriptional Reprogramming Leads to Immunotherapeutic Vulnerabilities in Myeloma,” Nature Cell Biology 23, no. 11 (2021): 1199-1211.

[48] S. M. Shaffer, M. C. Dunagin, S. R. Torborg, et al., “Rare Cell Variability and Drug-Induced Reprogramming as a Mode of Cancer Drug Resistance,” Nature 546, no. 7658 (2017): 431-435.

[49] X. Xu, W. Zhang, L. Xuan, et al., “PD-1 Signalling Defines and Protects Leukaemic Stem Cells From T Cell Receptor-Induced Cell Death in T Cell Acute Lymphoblastic Leukaemia,” Nature Cell Biology 25, no. 1 (2023): 170-182.

[50] A. Butler, P. Hoffman, P. Smibert, E. Papalexi, and R. Satija, “Integrating Single-Cell Transcriptomic Data Across Different Conditions, Technologies, and Species,” Nature Biotechnology 36, no. 5 (2018): 411-420.

[51] I. Korsunsky, N. Millard, J. Fan, et al., “Fast, Sensitive and Accurate Integration of Single-Cell Data With Harmony,” Nature Methods 16, no. 12 (2019): 1289-1296.

[52] J. M. Granja, M. R. Corces, S. E. Pierce, et al., “ArchR Is a Scalable Software Package for Integrative Single-Cell Chromatin Accessibility Analysis,” Nature Genetics 53, no. 3 (2021): 403-411.

[53] C. Y. McLean, D. Bristor, M. Hiller, et al., “GREAT Improves Functional Interpretation of Cis-Regulatory Regions,” Nature Biotechnology 28, no. 5 (2010): 495-501.

[54] S. Aibar, C. B. Gonzalez-Blas, T. Moerman, et al., “SCENIC: Single-Cell Regulatory Network Inference and Clustering,” Nature Methods 14, no. 11 (2017): 1083-1086.

[55] R. L. Camp, M. Dolled-Filhart, and D. L. Rimm, “X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization,” Clinical Cancer Research 10, no. 21 (2004): 7252-7259.

[56] C. Chen, C. Liang, S. Wang, et al., “Expression Patterns of Immune Checkpoints in Acute Myeloid Leukemia,” Journal of Hematology & Oncology 13, no. 1 (2020): 28.

[57] J. M. Fernandez, V. de la Torre, D. Richardson, et al., “The BLUEPRINT Data Analysis Portal,” Cell Systems 3, no. 5 (2016): 491-495.

[58] M. Schubert, B. Klinger, M. Klunemann, et al., “Perturbation-Response Genes Reveal Signaling Footprints in Cancer Gene Expression,” Nature Communications 9, no. 1 (2018): 20.

[59] T. Wu, E. Hu, S. Xu, et al., “ClusterProfiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data,” Innovations 2, no. 3 (2021): 100141.

[60] V. Bergen, M. Lange, S. Peidli, F. A. Wolf, and F. J. Theis, “Generalizing RNA Velocity to Transient Cell States Through Dynamical Modeling,” Nature Biotechnology 38, no. 12 (2020): 1408-1414.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.